Gene test picks patients for targeted immunotherapy trial
NCT ID NCT07300891
First seen Jan 07, 2026 · Last updated Jun 13, 2026 · Updated 24 times
Summary
This study tests a drug called tislelizumab in about 72 adults with advanced solid tumors that no longer respond to standard treatments. Only patients with a specific gene signature (T cell inflamed GEP score) are eligible. The drug is given every three weeks to see if it can shrink tumors or slow disease progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY SOLID CANCER PATIENTS UNEXPOSED TO IMMUNOTHERAPY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.